The risk of a biosimilar void in Europe
by Giuliana Miglierini The undergoing revision of the pharmaceutical legislation aims, among others, to redefine data protection to…
The UK’s statutory scheme revision for branded medicines
by Giuliana Miglierini The amendment of the statutory schemeregulating the increase in pricing and consequent clawback payments of…
What happens after IP loss of protection
by Giuliana Miglierini What does it happen under a competitiveness perspective once intellectual property (IP) protection for medicinal…